Biogen’s stock slides on soft guidance and a decline in sales of MS drugs
Sales of an Alzheimer’s disease treatment were better than expected, but that and a quarterly beat wasn’t enough to offset ...
pharmaphorum3d
Denali slides after ALS drug flunks clinical test
the drug remains in development for multiple sclerosis. "We remain deeply committed to fully understanding the effects of DNL343 in ALS and will further evaluate the data before determining next ...